ClinicalTrials.gg
CompletedNCT00360568Updated Jan 16, 2015Results posted

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

A Phase 3 interventional study of Levodopa-carbidopa intestinal gel and CADD-Legacy® 1400 ambulatory infusion pump in Dyskinesias, Parkinson's Disease and Severe Motor Fluctuations, sponsored by AbbVie (prior sponsor, Abbott). Completed at 22 sites in 3 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Dyskinesias with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyskinesias · United States.

Enrollment
36th of 82
62 · median 41
Started
2009
with 6 others
Phase 3
24 of 101
none open now
Registered
23rd of 101
by date
Lead sponsor
4 of 101
AbbVie (prior sponsor, Abbott)

Among the 101 studies in Dyskinesias with a site in United States, this one is the 36th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2009, is one of 24 in phase 3, and was the 23rd registered.

Dyskinesias

179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.

Browse Dyskinesias studies →

Open to participants now

8 of the 101 studies in Dyskinesias with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Dyskinesias with a site in United States, or all of them as a file.
02

Study summary

Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.

Read the detailed description

Study S187.3.003 (NCT00360568) is a Phase 3, 12-month, open-label, multicenter continuation treatment study of the safety, tolerability, and efficacy of levodopa-carbidopa intestinal gel (LCIG) in the treatment of participants with levodopa-responsive Parkinson's disease (PD) with persistent motor fluctuations despite optimized treatment with available PD medications. All participants received LCIG.

Only participants who completed 12 weeks of double-blind, double-dummy treatment in Study S187.3.001 or S187.3.002 (NCT00357994/ NCT00660387) qualified for enrollment in this 12-month continuation treatment study.

03

Conditions studied

  • Dyskinesias
  • Parkinson's Disease
  • Severe Motor Fluctuations

Keywords

  • carbidopa
  • severe motor fluctuations
  • intestinal gel
  • levodopa
  • efficacy
  • levodopa carbidopa intestinal gel
  • dyskinesia
  • Parkinson's Disease
  • Duodopa
  • levodopa-carbidopa
  • DUOPA
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic Parkinson's disease (PD) according to United Kingdon Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Levodopa-responsive with severe motor fluctuations
  • Completion of protocol S187.3.001 (NCT00357994) or S187.3.002 (NCT00660387) and continue to meet the inclusion criteria for the preceding study

Exclusion criteria

Exclusion Criteria:

  • Patients with medically relevant abnormal findings (labs, [ECG], physical examination, adverse events, psychiatric, neurological or behavioral disorders, etc.) at end of the double-blind phase (Week 12) of Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Levodopa-Carbidopa Intestinal Gel (LCIG)

    All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks). Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances.

    Drug: Levodopa-carbidopa intestinal gel · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: PEG tube · Device: J-tube

Interventions

  • DrugLevodopa-carbidopa intestinal gel

    Drug pages: Levodopa · Carbidopa

    Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).

  • DeviceCADD-Legacy® 1400 ambulatory infusion pump
  • DevicePEG tube

    percutaneous endoscopic gastrostomy tube

  • DeviceJ-tube

    jejunal tube

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs

    AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

    Time frame: From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J, plus 30 days.

  2. Number of Participants With Device Complications

    Complications of the infusion device were collected. Pump, intestinal tube, PEG, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and device site reaction.

    Time frame: 12 months

  3. Number of Participants With Potentially Clinically Significant Values for Hematology Parameters

    Terms abbreviated in the table include females (f) and males (m).

    Time frame: 12 months

  4. Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

    Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).

    Time frame: 12 months

  5. Number of Participants With Potentially Clinically Significant Vital Sign Parameters

    Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: 12 months

  6. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

    Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: 12 months

  7. Number of Participants With Sleep Attacks at Baseline and Endpoint

    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  8. Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)

    The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire-setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

    Time frame: Baseline, Post-baseline (up to Month 12)

  9. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint

    The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions concerning problems with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  10. Number of Participants With Confirmed Cases of Melanoma

    A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination/end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

    Time frame: up to Month 12

  11. Number of Participants With Clinically Significant Neurological Examination Findings

    The neurologic examination was to be done during "On" time. The neurological examination assessed: cranial nerves - assessment of cranial nerves II - XII, excluding fundoscopic examination; motor system - assessment of tone, strength, and abnormal movements; sensory system - including light touch, pinprick, joint position, and vibratory sense; reflexes - assessment of deep tendon reflexes and plantar responses (Babinski sign); coordination - assessment of upper and lower extremities; gait - assessment of base and tandem gait; station - assessment of posture and stability.

    Time frame: up to 12 months

  12. Columbia-Suicide Severity Rating Scale (C-SSRS) Findings

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

    Time frame: up to 12 months

  13. Number of Participants Taking at Least 1 Concomitant Medication During the Study

    Concomitant medications include medications started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.

    Time frame: 12 months

Secondary outcomes

  1. Change From Baseline in Average Daily "Off" Time at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  2. Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  3. Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Month 12

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  4. Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint

    The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  5. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  6. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  7. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  8. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  9. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  10. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  11. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  12. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  13. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  14. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  15. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  16. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  17. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  18. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  19. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint

    The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  20. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

    Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)

  21. Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint

    The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.

    Time frame: Baseline, Endpoint (Month 12 months or last post-baseline visit)

07

Results

Posted Jan 16, 2015

Participant flow

Participant flow — Overall Study
MilestoneLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)
Started3329
Completed3124
Not completed25
Withdrew: Adverse event12
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs

AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

Time frame:
From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J, plus 30 days.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Deaths000
TE Deaths000
>=1 SAE5914
>=1 TESAE5914
>=1 TEAE Leading to Study Termination123
>=1 TEAE312859
>=1 Severe TEAE51015
>=1 Possibly or ProbablyTreatment-Related TEAE282048
No TEAEs213
PrimaryNumber of Participants With Device Complications

Complications of the infusion device were collected. Pump, intestinal tube, PEG, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and device site reaction.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Device Complications
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
>=1 Complication262450
Pump Complication181634
Intestinal Tube Complication151631
PEG Complication111122
Stoma Complication121527
Other6410
PrimaryNumber of Participants With Potentially Clinically Significant Values for Hematology Parameters

Terms abbreviated in the table include females (f) and males (m).

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Red Blood Cells <2.0 10^12/L (f); <2.5 10^12/L (m)000
Haemoglobin <90 g/L (f); <100 g/L (m)011
Haematocrit <30% (f); <34% (m)112
White Blood Cells <2.8 10^9/L000
White Blood Cells >16.0 10^9/L000
Neutrophils, Absolute <1.2 10^9/L000
Lymphocytes >80%000
Lymphocytes, Absolute <.75 10^9/L202
Eosinophils >10%000
Monocytes >30%000
Platelet Count <95 10^9/L000
Platelet Count >700 10^9/L000
Mean Corpuscular Volume <60 fL000
Mean Corpuscular Volume >120 fL000
PrimaryNumber of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Sodium <126 mmol/L; n=33, 28, 61000
Sodium >156 mmol/L; n=33, 28, 61000
Albumin <25 g/L; n=27, 20, 47000
Albumin >70 g/L; n=27, 20, 47000
Potassium <3.0 mmol/L; n=33, 28, 61000
Potassium >6.0 mmol/L; n=33, 28, 61000
Creatinine >177 µmol/L; n=33, 28, 61000
Calcium <1.75 mmol/L; n=33, 28, 61000
Calcium >3.0 mmol/L; n=33, 28, 61000
Total Protein <45 g/L; n=33, 28, 61000
Total Bilirubin >2xULN; n=33, 28, 61000
Aspartate Aminotransferase >3xULN; n=33, 28, 61000
Alanine Aminotransferase >3xULN; n=33, 28, 61000
Gamma-glutamyl Transpeptidase >3x ULN;n=33, 28, 61112
Lactate dehydrogenase >3x ULN; n=33, 28, 61000
Alkaline Phosphatase >400 U/L; n=33, 28, 61000
Creatine Phosphokinase >3x ULN; n=33, 28, 61000
Non-fasting Glucose <2.78 mmol/L; n=33, 28, 61000
Non-fasting Glucose >16.0 mmol/L; n=33, 28, 61000
Uric Acid>500µmol/L(f);>590µmol/L(m);n=33, 28, 61000
Blood Urea Nitrogen >10.8 mmol/L; n=28, 22, 50303
Cholesterol >12.9 mmol/L; n=33, 28, 61000
Triglycerides >5.6 mmol/L; n=33, 28, 61000
PrimaryNumber of Participants With Potentially Clinically Significant Vital Sign Parameters

Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
SuSBP <=90 and >30 mm Hg ↓ from BL; n=33, 29, 62303
SuSBP >=180 and >40 mm Hg ↑ from BL; n=33, 29, 62123
StSBP <=90 and >30 mm Hg ↓ from BL; n=33, 29, 624711
StSBP >=180 and >40 mm Hg ↑ from BL; n=33, 29, 62000
OSBP: ↓ >=30 mm Hg Supine to Standing; n=33,29,6281119
SuDBP <=50 and >30 mm Hg ↓ from BL; n=33, 29, 62011
SuDBP >=105 and >30 mm Hg ↑ from BL; n=33, 29, 62112
StDBP <=50 and >30 mm Hg ↓ from BL; n=33, 29, 62101
StDBP >=105 and >30 mm Hg ↑ from BL; (n=33,29,62)213
ODBP: ↓ >=20 mm Hg Supine to Standing; n=33,29,627714
SuP <=50 and >30 bpm ↓ from BL; n=33, 29, 62101
SuP >=120 and >30 bpm ↑ from BL; n=33, 29, 62000
StP <=50 and >30 bpm ↓ from BL; n=33, 29, 62000
StP >=120 and >30 bpm ↑ from BL; n=33, 29, 62011
Temp >=38.3° and >=1.1°C ↑ from BL; n=33, 29, 62000
Weight <=7% ↓ from BL; n=33, 27, 605510
Weight >=7% ↑ from BL; n=33, 27, 608816
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
HR <=50 and >30 bpm ↓ from BL; n=33, 28, 61000
HR >=120 and >30 bpm ↑ from BL; n=33, 28, 61000
PR Interval <120 msec; n=33, 27, 60101
PR Interval >220 msec; n=33, 27, 60101
QTcB Interval >480 msec; n=33, 27, 60000
QTcB Interval >60 msec ↑ from BL; n=33, 27, 60000
QTcF Interval >480 msec; n=33, 27, 60000
QTcF Interval >60 msec ↑ from BL; n=33, 27, 60000
PrimaryNumber of Participants With Sleep Attacks at Baseline and Endpoint

To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Number · participants
Number of Participants With Sleep Attacks at Baseline and Endpoint
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Participants with >=1 Sleep Attacks at Baseline000
Participants with >=1 Sleep Attacks at Endpoint000
PrimarySummary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)

The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire-setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

Time frame:
Baseline, Post-baseline (up to Month 12)
Reported as:
Number · participants
Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
BL Pathological Gambling; n=33, 29, 62000
BL Trichotillomania; n=33, 29, 62000
BL Kleptomania; n=33, 29, 62000
BL Pyromania; n=33, 29, 62000
BL Intermittent Explosive Disorder; n=33, 29, 62000
BL Compulsive Buying; n=33, 29, 62011
BL Compulsive Sexual Behavior; n=33, 29, 62011
PBL Pathological Gambling; n=33, 27, 60000
PBL Trichotillomania; n=33, 27, 60000
PBL Kleptomania; n=33, 27, 60000
PBL Pyromania; n=33, 27, 60000
PBL Intermittent Explosive Disorder; n=33, 27, 60000
PBL Compulsive Buying; n=33, 27, 60101
PBL Compulsive Sexual Behavior; n=33, 27, 60202
PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint

The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions concerning problems with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline; n=33, 29, 626.1 ± 6.05.3 ± 6.35.7 ± 6.1
Change from Baseline at Endpoint; n=33, 27, 606.1 ± 6.05.0 ± 6.35.6 ± 6.1
PrimaryNumber of Participants With Confirmed Cases of Melanoma

A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination/end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

Time frame:
up to Month 12
Reported as:
Number · participants
Number of Participants With Confirmed Cases of Melanoma
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Number of Participants With Confirmed Cases of Melanoma000
PrimaryNumber of Participants With Clinically Significant Neurological Examination Findings

The neurologic examination was to be done during "On" time. The neurological examination assessed: cranial nerves - assessment of cranial nerves II - XII, excluding fundoscopic examination; motor system - assessment of tone, strength, and abnormal movements; sensory system - including light touch, pinprick, joint position, and vibratory sense; reflexes - assessment of deep tendon reflexes and plantar responses (Babinski sign); coordination - assessment of upper and lower extremities; gait - assessment of base and tandem gait; station - assessment of posture and stability.

Time frame:
up to 12 months
Reported as:
Number · participants
Number of Participants With Clinically Significant Neurological Examination Findings
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Cranial Nerve000
Motor System325
Sensory System213
Reflexes112
Coordination101
Gait224
Station224
PrimaryColumbia-Suicide Severity Rating Scale (C-SSRS) Findings

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

Time frame:
up to 12 months
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS) Findings
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Participants with Suicidal Ideations000
Participants with Suicidal Ideations Only000
Participants with Suicidal Behaviors000
Participants with Suicidal Behaviors or Ideations000
PrimaryNumber of Participants Taking at Least 1 Concomitant Medication During the Study

Concomitant medications include medications started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants Taking at Least 1 Concomitant Medication During the Study
participantsLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Number of Participants Taking at Least 1 Concomitant Medication During the Study332962
SecondaryChange From Baseline in Average Daily "Off" Time at Endpoint

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · hours
Change From Baseline in Average Daily "Off" Time at Endpoint
hoursLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline2.87 ± 2.185.18 ± 2.053.92 ± 2.40
Change from Baseline at Endpoint-0.42 ± 2.67-2.34 ± 2.78-1.30 ± 2.86
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · hours
Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint
hoursLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline1.09 ± 2.070.82 ± 1.540.97 ± 1.84
Change from Baseline at Endpoint-0.58 ± 2.180.15 ± 2.17-0.24 ± 2.19
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.394
SecondaryChange From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Month 12

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · hours
Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Month 12
hoursLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline12.04 ± 2.4210.00 ± 2.6211.11 ± 2.69
Change from Baseline at Endpoint1.00 ± 2.582.19 ± 3.701.54 ± 3.17
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = <0.001
SecondaryClinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint

The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
CGI-S at Baseline; n=32, 28, 603.0 ± 1.33.7 ± 1.33.3 ± 1.3
CGI-I at Endpoint; n=33, 29, 622.1 ± 1.22.3 ± 1.62.2 ± 1.4
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline1.6 ± 1.81.2 ± 1.01.4 ± 1.5
Change from Baseline at Endpoint0.3 ± 1.90.7 ± 1.70.5 ± 1.8
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.055
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline8.6 ± 6.512.1 ± 7.010.1 ± 6.9
Change from Baseline at Endpoint0.5 ± 3.4-1.0 ± 7.0-0.2 ± 5.3
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.766
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline16.2 ± 12.719.0 ± 10.517.4 ± 11.8
Change from Baseline at Endpoint1.5 ± 7.0-0.5 ± 10.40.6 ± 8.6
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.571
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline26.4 ± 18.932.4 ± 16.129.0 ± 17.8
Change from Baseline at Endpoint2.3 ± 9.0-1.0 ± 15.00.9 ± 12.0
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.583
SecondaryChange From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline5.8 ± 2.77.0 ± 3.26.3 ± 3.0
Change from Baseline at Endpoint-1.6 ± 2.5-1.4 ± 3.0-1.5 ± 2.7
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline22.2 ± 17.332.8 ± 17.026.9 ± 17.8
Change from Baseline at Endpoint1.5 ± 12.7-3.5 ± 13.4-0.7 ± 13.2
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.670
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline27.6 ± 24.143.8 ± 25.434.7 ± 25.8
Change from Baseline at Endpoint2.3 ± 19.5-8.5 ± 18.6-2.5 ± 19.7
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.341
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline25.9 ± 24.839.4 ± 21.331.9 ± 24.1
Change from Baseline at Endpoint0.4 ± 14.0-6.7 ± 19.9-2.8 ± 17.1
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.220
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline20.1 ± 20.326.3 ± 17.222.8 ± 19.1
Change from Baseline at Endpoint4.0 ± 16.41.9 ± 18.13.1 ± 17.1
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.174
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline16.4 ± 21.323.8 ± 19.019.7 ± 20.5
Change from Baseline at Endpoint0.2 ± 15.2-6.3 ± 20.7-2.7 ± 18.0
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.259
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline11.9 ± 18.217.1 ± 17.814.2 ± 18.0
Change from Baseline at Endpoint1.8 ± 17.2-2.7 ± 15.5-0.2 ± 16.5
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.922
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline15.0 ± 14.124.8 ± 18.919.3 ± 16.9
Change from Baseline at Endpoint1.3 ± 16.33.8 ± 16.72.4 ± 16.4
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.258
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline15.9 ± 16.331.7 ± 23.222.9 ± 21.0
Change from Baseline at Endpoint8.3 ± 18.4-1.9 ± 15.33.8 ± 17.7
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.104
SecondaryChange From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Endpoint32.1 ± 25.834.9 ± 22.933.3 ± 24.4
Change from Baseline at Endpoint-2.8 ± 18.81.0 ± 19.5-1.1 ± 19.0
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.650
SecondaryChange From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint

The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline0.778 ± 0.1440.676 ± 0.1580.733 ± 0.158
Change from Baseline at Endpoint-0.009 ± 0.173-0.006 ± 0.220-0.008 ± 0.193
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.759
SecondaryChange From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint

The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

Time frame:
Baseline, Endpoint (Month 12 or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline76.7 ± 16.262.1 ± 22.070.2 ± 20.2
Change from Baseline at Endpoint-0.9 ± 15.14.5 ± 15.51.5 ± 15.4
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.459
SecondaryChange From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint

The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.

Time frame:
Baseline, Endpoint (Month 12 months or last post-baseline visit)
Reported as:
Mean · units on a scale
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint
units on a scaleLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
Baseline22.1 ± 15.327.0 ± 17.224.3 ± 16.2
Change from Baseline at Endpoint1.1 ± 9.7-1.8 ± 9.0-0.2 ± 9.4
Statistical analysis
  • LCIG (All Participants) · t-test, 2 sided · p = 0.899

Adverse events

Collected over From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J (up to 52 weeks), plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LCIG (Previous: LCIG + Placebo Capsules)—5/33 (15.2%)29/33 (87.9%)
LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)—9/29 (31%)26/29 (89.7%)
LCIG (All Participants)—14/62 (22.6%)55/62 (88.7%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
COMPLICATION OF DEVICE INSERTIONGeneral disorders1/332/293/62
PNEUMONIAInfections and infestations0/332/292/62
ANGINA PECTORISCardiac disorders0/331/291/62
ABDOMINAL PAINGastrointestinal disorders1/331/292/62
FAECALOMAGastrointestinal disorders0/331/291/62
INTESTINAL ISCHAEMIAGastrointestinal disorders0/331/291/62
INTESTINAL PERFORATIONGastrointestinal disorders0/331/291/62
PERITONITISGastrointestinal disorders0/331/291/62
ASTHENIAGeneral disorders1/331/292/62
CHOLECYSTITISHepatobiliary disorders0/331/291/62
Most frequent other events
Showing 10 of 56
Most frequent other events
EventLCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)LCIG (All Participants)
INCISION SITE ERYTHEMAInjury, poisoning and procedural complications7/3311/2918/62
VITAMIN B6 DECREASEDInvestigations8/335/2913/62
INSOMNIAPsychiatric disorders2/337/299/62
FALLInjury, poisoning and procedural complications7/336/2913/62
POSTOPERATIVE WOUND INFECTIONInfections and infestations5/336/2911/62
CONSTIPATIONGastrointestinal disorders4/335/299/62
NAUSEAGastrointestinal disorders4/335/299/62
POST PROCEDURAL DISCHARGEInjury, poisoning and procedural complications3/335/298/62
URINARY TRACT INFECTIONInfections and infestations5/334/299/62
BLOOD HOMOCYSTEINE INCREASEDInvestigations5/332/297/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)LCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)Total
Mean63.6 ± 9.064.8 ± 6.664.1 ± 7.9
Age, Customized
Age, Customized(participants)LCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)Total
<65 years191332
>=65 years141630
Sex: Female, Male
Sex: Female, Male(Participants)LCIG (Previous: LCIG + Placebo Capsules)LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules)Total
Female10818
Male232144
08

Study locations

22 sites
  • Site Reference ID/Investigator# 45869
    Birmingham, Alabama 35222, United States
  • Site Reference ID/Investigator# 45834
    Fountain Valley, California 92708, United States
  • Site Reference ID/Investigator# 45854
    Los Angeles, California 90033, United States
  • Site Reference ID/Investigator# 45856
    Oceanside, California 92056, United States
  • Site Reference ID/Investigator# 45859
    Washington, District of Columbia 20007, United States
  • Site Reference ID/Investigator# 45857
    Bradenton, Florida 34205, United States
  • Site Reference ID/Investigator# 45863
    Gainesville, Florida 32610, United States
  • Site Reference ID/Investigator# 45836
    Port Charlotte, Florida 33890, United States
  • Site Reference ID/Investigator# 45874
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator# 45868
    Lexington, Kentucky 40536, United States
  • Site Reference ID/Investigator# 45862
    Baltimore, Maryland 21201, United States
  • Site Reference ID/Investigator# 45861
    St. Louis, Missouri 63110, United States
  • Site Reference ID/Investigator# 45873
    New York, New York 10032, United States
  • Site Reference ID/Investigator# 45878
    Cincinnati, Ohio 45267, United States
  • Site Reference ID/Investigator# 45850
    Cleveland, Ohio 44195-0001, United States
  • Site Reference ID/Investigator# 45887
    Burlington, Vermont 05401, United States
  • Site Reference ID/Investigator# 45828
    Bochum, 44791, Germany
  • Site Reference ID/Investigator# 45829
    Bremerhaven, 27574, Germany
  • Site Reference ID/Investigator# 45825
    Hanover, 30625, Germany
  • Site Reference ID/Investigator# 54402
    Tuebingen, 72076, Germany
  • Site Reference ID/Investigator# 45884
    Auckland, 1010, New Zealand
  • Site Reference ID/Investigator# 45885
    Hamilton, 3204, New Zealand
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 2 years 3 months after primary completion. A results delay was requested in Oct 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2006
First posted
Aug 4, 2006
Start
Jun 2009
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Oct 25, 2013
Results first posted
Jan 16, 2015
Last update
Jan 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00360568
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Aug 4, 2006
Start date
Jun 2009
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Jan 16, 2015
Last update
Jan 16, 2015

Study contacts

Janet Benesh
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion